PROMACTA®

Eltrombopag was approved by the FDA under the trade name Promacta® in November 2008, for the treatment of chronic ITP in adults who have had an insufficient response to corticosteroids, immunoglobulins or following surgical removal of the spleen. It was approved for use in Europe in March 2010 under the trade name Revolade as an oral treatment for thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP). Eltrombopag is also approved under the trade name Revolade in Japan, Venezuela, Kuwait, Chile and Russia. Eltrombopag was discovered as a result of a research collaboration between GSK and Ligand Pharmaceuticals and developed by GSK.

In 2012, GSK received FDA approval for a new indication for Promacta. Promacta is now marketed in the U.S. for the treatment of thrombocytopenia in patients with chronic hepatitis C virus (HCV) to allow them to initiate and maintain interferon-based therapy. Promacta is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts.

Clinical Trials:

Phase II study in patients with oncology-related thrombocytopenia is ongoing
Phase 1 study in patients with thrombocytopenia caused by myelodysplastic syndrome is ongoing

GSK-5921

In 2008, Ligand entered into an exclusive, worldwide license agreement with GSK. Whereby, we granted GSK the exclusive right to develop, manufacture and commercialize GSK-5921, as well as all other TPO-related molecules discovered by us.